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Selenium in the form of selenized yeast was reported by Clark et al. 
to have possible lung cancer chemopreventive beneﬁts based on a 
secondary observation emanating from a large skin cancer prevention 
trial. (JAMA 1996; 276: 1957-1963). Since that time, epidemiologic, 
in vitro, and therapeutic research studies have continued to support 
the hypothesis that non-toxic selenium supplementation may decrease 
the risk of aerodigestive cancer in persons at high risk, e.g., those 
with resected bronchogenic cancer. Since October 2000, the Eastern 
Cooperative Oncology Group (ECOG) with support from the National 
Cancer Institute Division of Cancer Prevention (NCI-DCP) has been 
conducting an intergroup double blind placebo controlled trial using 
200 micrograms of Selenium in a 2:1 randomization versus placebo. 
Eligibility requirements include completely resected Stage I (T1 or T2, 
N0) non-small cell cancer of the lung with a minimum of 1 negative 
mediastinal lymph node. Pts must have normal level of selenium / 
vitamin intake, satisfactory liver function, a negative chest x-ray and 
no other evidence of recurrence. Enrollment is allowed from 6 to 36 
months post thoracotomy. A four wk run-in period is required during 
which pts must take at least 75% of the study drug to document compli-
ance. As of March 7, 2007, 1268 pts have enrolled out of a projected 
total study size of 1960 participants. Treatment is for 48 months. Study 
endpoints include cancer recurrence, incidence of second primary lung 
tumors (SPTs), and/or toxicity. Treatment appears to be extremely well 
tolerated in this study. As of December 2006, a total of 363 patients 
on randomized step have reported treatment-related toxicities. Only 
six of them reported toxicities of grade 3 or higher as a worst toxicity. 
133 grade 3, 4, or 5 severe adverse events have been reported with no 
difference between study drug and placebo. A total of six cooperative 
groups are participating in this ambitious project. Selenium appears to 
be very well tolerated in this setting. Accrual is projected to continue 
until 1960 pts have enrolled or until 90 SPTs have occurred. 
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Usefulness of autofluorescence bronchoscopy for detecting 
bronchial premalignant lesions
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Background: Autoﬂuorescence bronchoscopy (AFB), when used as 
an adjunct to conventional white light bronchoscopy (WLB) improves 
the bronchoscopist’s ability to localized small intraepithelial lesions. 
Current study was undertaken to evaluate prevalence of preinvasive 
intraepithelial lesions (dysplasia II-III & CIS) and efﬁcacy of additional 
AFB system to WLB in comparison with WLB alone.
Methods: In patients with suspicion of lung cancer or follow-up ones 
with known lung cancer, WLB (Pentax; BP 3500, Japan) and AFB 
(Richard Wolf, Germany) were done and all subjects with endoscopic 
abnormalities underwent biopsies from January 2005 to December 2005.
Results: 169 patients (134 suspected to have lung cancer radiological-
ly, 18 with known lung cancer, and 17 with initial abnormal WLB vi-
sual ﬁndings) were enrolled. Overall preinvasive intraepithelial lesions 
were detected in 6.5% (n=11). Biopsy based sensitivity of WLB+AFB 
and WLB alone for detecting preinvasive intraepithelial lesions was 
77.8% compared with 22.2% (relative ratio 3.5, 95% CI 0.93-13.24). 
Corresponding speciﬁcity was 56.9% compared with 89.2% (relative 
ratio 0.64, 95% CI 0.54-0.75). The positive predicitve value was 6% 
and 3%, and the negative predictive value was 94% and 87%, respec-
tively, for WLB+AFB and WLB alone.
Conclusions: WLB+AFB was superior to WLB alone in detecting 
preinvasive intraepithelial lesions, but general use of AFB as a screen-
ing tool seems to be limited in suspected or known lung cancer group 
because of low prevalence. It is necessary of further study for precise 
indication for AFB among the lung cancer risk groups.
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We performed this study to investigate the aberrant methylation proﬁle 
of the cancer-related genes in Korean non-small cell lung cancer 
(NSCLC) that previously exhibited high frequencies of methylation 
in Western populations. The aberrant promoter methylation of eight 
genes (GSTP1, p16, FHIT, APC, RASSF1A, hMLH1, hMSH2, AGT) 
was determined by MSP in 99 surgically resected NSCLCs and their 
corresponding nonmalignant lung tissues. Methylation in the tumor 
samples was detected at 15% for GSTP1, 22% for p16, 34% for FHIT1, 
48% for APC, 40% for RASSF1A, 18% for hMLH1, 8% for hMSH2 
and 21% for AGT, whereas it occurred at lower frequencies in the 
corresponding nonmalignant lung tissues, particularly in the p16 (1%) 
and RASSF1A (1%) genes. These results suggest that the methyla-
tion proﬁles of NSCLCs in a Korean population are similar to those in 
Western populations.
